RxDoctor Payments Data

Mohammad Malekzadegan

Pulmonary Disease · Riverside, CANPI 1881085207

Payments from drug & device makers

$1,756in general payments, 2019–2025

Across 14 payments — averaging $125.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • AstraZeneca$250
  • GSK$44
  • Boehringer Ingelheim$32

What the payments were for

  • Travel & lodging$1,20469%
  • Food & beverage$55331%

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific9$1,430
AstraZeneca2$250
GSK2$44
Boehringer Ingelheim1$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,756 in reported general payments places this provider in the 50th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$259,264
Medicare patients
338
Services billed
1,473

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Riverside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →